NCT07071415
Overdiagnosis and Breast Cancer Screening Decisions
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
Notable Results posted: Nov 9, 2026 Show 4 more changesShow less
- Eligibility criteria expanded, about 3 words
- Enrollment target: 308 to 307
- Secondary endpoints revised (2)
- Primary endpoint revised
- Minor Enrollment target: 311 to 308v4
Minor Trial status: Recruiting to Completedv3 Show 4 more changesShow less
- Enrollment target: estimated 300 to confirmed 311
- Primary and study completion dates changed from estimate of Aug 2025 to Oct 20, 2025
- Start date: Jul 23, 2025 to Aug 19, 2025
- Site details revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jul 2025 to Jul 23, 2025
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (2)
Arms and interventions
Participants in this arm will be shown a decision aid in which risk of overdiagnosis is low.
Participants in this arm will be shown a decision aid in which risk of overdiagnosis is moderate.
Participants in this arm will be shown a decision aid in which risk of overdiagnosis is high.
Participants in this arm will be shown a video about breast cancer screening that is identical in all ways but contains no information about overdiagnosis.
Behavioral: Breast cancer screening decision aid -- low risk, Breast cancer decision aid -- moderate risk, Breast cancer screening decision aid -- high risk
Other: Control condition
Sites
1 site in 1 country
- Yale School of MedicineNew Haven, Connecticut, United States